Mitchel is a reporter for MDedge based in the Philadelphia area. He started with the company in 1992, when it was International Medical News Group (IMNG), and has since covered a range of medical specialties. Mitchel trained as a virologist at Roswell Park Memorial Institute in Buffalo, and then worked briefly as a researcher at Boston Children's Hospital before pivoting to journalism as a AAAS Mass Media Fellow in 1980. His first reporting job was with Science Digest magazine, and from the mid-1980s to early-1990s he was a reporter with Medical World News. @mitchelzoler
News
Experts elevate new drugs for diabetic kidney disease
A consensus statement from the ADA and KDIGO recommends more aggressive combined use of several newer, and costly, drug classes to slow...
News
SGLT2 inhibitors cut AFib risk in real-word analysis
Observational data add to a growing link between SGLT2 inhibitor treatment and atrial fibrillation prevention in people with type 2 diabetes.
News
Antidiabetes drug costs keep patients away
Patients with diabetes and high med co-pays had worse fill rates, but even with low copays uptake of effective but expensive antidiabetes drugs...
News
Tirzepatide powers ‘unprecedented’ weight loss in SURMOUNT-1
The twincretin tirzepatide produced jaw-dropping levels of weight loss in people with obesity and no diabetes compared with placebo in the...
News
ADA prioritizes heart failure in patients with diabetes
Patients with diabetes should have annual screening for biomarkers of early-stage heart failure, and treatment should prioritize an SGLT2...
News
Newly approved tirzepatide’s retail price announced
The recently approved twincretin will carry a U.S. retail price similar to one of its main competitors, semaglutide, but patient discounts will be...
News
Tirzepatide (Mounjaro) approved for type 2 diabetes
Endocrinologists voice enthusiasm for the first approved agent for patients with type 2 diabetes that is a dual incretin agonist, but they also...
News
Combo of SGLT2 inhibitor + GLP-1 RA boosts diabetes survival
Survival of patients with type 2 diabetes and CVD rose by 80% when they received both an SGLT2 inhibitor and GLP-1 RA, compared with either class...
News
Empagliflozin rapidly improves acute heart failure symptoms in hospitalized patients
Empagliflozin showed symptomatic benefits in patients hospitalized for acute heart failure after 2 weeks in a secondary analysis from the EMPULSE...
News
SCORED: Sotagliflozin shows robust MACE benefit
Trial results in patients with diabetes, CKD, and high CVD risk showed robust benefits across MACE outcomes, distinguishing sotagliflozin from the...
News
FDA okays semaglutide higher dose, 2 mg/week, for type 2 diabetes
The 2-mg weekly dose is associated with greater A1c reduction and more weight loss.
News
Empagliflozin scores topline win in EMPA-KIDNEY trial
Researchers stopped the 6,600-patient EMPA-KIDNEY trial sooner than expected because it positively met prespecified efficacy criteria in a trial...
News
Finerenone + SGLT2 inhibitor of benefit in diabetes with CKD?
Results from FIDELITY, a prespecified analysis of data from two pivotal trials of finerenone, hints of an additive benefit with SGLT2 inhibitors...